UNICREDIT BANK/CALL/AMGEN/320/0.1/18.12.24 | Real-time BOERSE MUENCHEN 07:42:01 2024-07-11 am EDT | ||
| 2.62 EUR | +3.56% |
|
| Current month | +18.78% | ||
| 1 month | +49.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 2.62 | +3.56% |
| 24-07-10 | 2.53 | +17.67% |
| 24-07-09 | 2.15 | +4.88% |
| 24-07-08 | 2.05 | +2.50% |
| 24-07-05 | 2 | +5.26% |
Real-time BOERSE MUENCHEN
Last update July 11, 2024 at 07:42 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC4Z5D |
| ISIN | DE000HC4Z5D5 |
| Date issued | 2023-03-14 |
| Strike | 320 $ |
| Maturity | 2024-12-18 (160 Days) |
| Parity | 10 : 1 |
| Emission price | 0.85 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.47 € |
|---|---|
| Lowest since issue | 0.3 € |
| Spread | 0.05 € |
| Spread % | 1.90% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
321.7
USD
Average target price
316.1
USD
Spread / Average Target
-1.72%
- Stock Market
- Warrants
- Warrant
